Metabolomics and ischaemic heart disease

Clinical Science

Volumn 124, Issue 5, 2013, Pages 289-306

  Rasmiena, Aliki A ^a   Ng, Theodore W ^a   Meikle, Peter J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Atherosclerosis; Biomarker; Ischaemic heart disease; Lipidomics; Mass spectrometry; Metabolite; Metabolomics; Risk

Indexed keywords

7BETA HYDROXYCHOLESTEROL; ACETYLCARNITINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CD36 ANTIGEN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROSTANE DERIVATIVE; LINOLEIC ACID; LIPIDOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; OXYSTEROL; PALMITIC ACID; ROSUVASTATIN; TAURINE;

ATHEROSCLEROTIC PLAQUE; BIOINFORMATICS; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

HUMANS; LIPID METABOLISM; METABOLOMICS; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 84872260070     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120268     Document Type: Review

References (152)

1. World Health Organization (2011) Global Atlas on Cardovascular Disease Prevention and Control. (S. Mendis, S., Puska, P. and Norrving, B., eds), World Health Organization, Geneva
2. Murphy, S. L., Xu, J. Q. and Kochanek, K. D. (2012) Deaths: preliminary data for 2010: National Vital Statistics Reports., vol. 60, no. 4, National Center for Health Statistics, Hyattsville, MD
3. AIHW (2011) Cardiovascular disease: Australian facts 2011, Australian Institute of Health and Welfare, Canberra
4. Gaziano, T. A. (2005) Cardiovascular disease in the developing world and its cost-effective management. Circulation 112, 3547-3553
5. AIHW (2010) Australia's Health 2010, Australian Institute of Health and Welfare, Canberra 140-145
6. Mackay, J. and Mensah, G (2004) Atlas of heart disease and stroke, World Health Organization, Geneva
7. Naghavi, M., Falk, E., Hecht, H. S., Jamieson, M. J., Kaul, S., Berman, D., Fayad, Z., Budoff, M. J., Rumberger, J., Naqvi, T. Z. et al. (2006) From vulnerable plaque to vulnerable patient - Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am. J. Cardiol. 98, 2H-15H
8. Den Ruijter, H. M., Peters, S. A., anderson, T. J., Britton, A. R., Dekker, J. M., Eijkemans, M. J., Engstrom, G., Evans, G. W., de Graaf, J., Grobbee, D. E. et al. (2012) Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA, J. Am. Med. Assoc. 308, 796-803
9. Wang, T. J., Wollert, K. C., Larson, M. G., Coglianese, E., McCabe, E. L., Cheng, S., Ho, J. E., Fradley, M. G., Ghorbani, A., Xanthakis, V. et al. (2012) Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation 126, 1596-1604
10. Yeboah, J., McClelland, R. L., Polonsky, T. S., Burke, G. L., Sibley, C. T., O'Leary, D., Carr, J. J., Goff, D. C., Greenland, P. and Herrington, D. M. (2012) Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA, J. Am. Med. Assoc. 308, 788-795
11. Libby, P. and Aikawa, M. (2002) Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. 8, 1257-1262
12. Tabas, I. (2005) Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25, 2255-2264
13. Thom, T., Haase, N., Rosamond, W., Howard, V. J., Rumsfeld, J., Manolio, T., Zheng, Z.J., Flegal, K., O'Donnell, C., Kittner, S. et al. (2006) Heart disease and stroke statistics - 2006 update. Circulation 113, e85-e151
14. Tweeddale, H., Notley-McRobb, L. and Ferenci, T. (1998) Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. J. Bacteriol. 180, 5109-5116
15. Oliver, S. G., Winson, M. K., Kell, D. B. and Baganz, F. (1998) Systematic functional analysis of the yeast genome. Trends Biotechnol. 16, 373-378
16. Fiehn, O. (2001) Combining genomics, metabolome analysis and biochemical modelling to understand metabolic networks. Comp. Funct. Genomics 2, 155-168
17. Griffin, J. L., Atherton, H., Shockcor, J. and Atzori, L. (2011) Metabolomics as a tool for cardiac research. Nat. Rev. Cardiol. 8, 630-643
18. Lusis, A. J., Mar, R. and Pajukanta, P. I. (2004) Genetics of atherosclerosis. Ann. Rev. Genomics Hum. Genet. 5, 189-218
19. Hakonarson, H., Grant, S. F. A., Bradfield, J. P., Marchand, L., Kim, C. E., Glessner, J. T., Grabs, R., Casalunovo, T., Taback, S. P., Frackelton, E. C. et al. (2007) A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448, 591-594
20. Reed, D. R., Ding, Y., Xu, W., Cather, C., Green, E. D. and Price, R. A. (1996) Extreme obesity may be linked to markers flanking the human OB gene. Diabetes 45, 691-694
21. Waterman, C. L., Kian-Kai, C. and Griffin, J. L. (2010) Metabolomic strategies to study lipotoxicity in cardiovascular disease. Biochim. Biophys. Acta 1801, 230-234
22. A. Thomas, S. L., Chaurand, P., Deglon, J., Mangin, P., Mach, F., Steffens, S., Wolfender, J.-L. and Staub, C. (2011) Mass spectrometry for the evaluation of cardiovascular disease based on proteomics and lipidomics. Thromb. Haemostasis 106, 20-33
23. Becker, S., Kortz, L., Helmschrodt, C., Thiery, J. and Ceglarek, U. (2012) LC-MS-based metabolomics in the clinical laboratory. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 883-884, 68-75
24. Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., Dugar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y. M. et al. (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63
25. Giovane, A., Balestrieri, A. and Napoli, C. (2008) New insights into cardiovascular and lipid metabolomics. J. Cell. Biochem. 105, 648-654
26. Dunn, W. B., Goodacre, R., Neyses, L. and Mamas, M. (2011) Integration of metabolomics in heart disease and diabetes research: current achievements and future outlook. Bioanalysis 3, 2205-2222
27. Rhee, E. P. and Gerszten, R. E. (2012) Metabolomics and cardiovascular biomarker discovery. Clin. Chem. 58, 139-147
28. Berne, C. and Siewert-Delle, A. (2005) Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc. Diabetol. 4, 7
29. Otvos, J. D., Jeyarajah, E. J. and Bennett, D. W. (1991) Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin. Chem. 37, 377-386
30. Otvos, J. D., Jeyarajah, E. J., Bennett, D. W. and Krauss, R. M. (1992) Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin. Chem. 38, 1632-1638
31. Soininen, P., Kangas, A. J., Wurtz, P., Tukiainen, T., Tynkkynen, T., Laatikainen, R., Jarvelin, M. R., Kahonen, M., Lehtimaki, T., Viikari, J. et al. (2009) High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134, 1781-1785
32. Mayr, M. (2008) Metabolomics. Circ. Cardiovasc. Gen. 1, 58-65
33. Schuhmann, K., Almeida, R., Baumert, M., Herzog, R., Bornstein, S. R. and Shevchenko, A. (2012) Shotgun lipidomics on a LTQ Orbitrap mass spectrometer by successive switching between acquisition polarity modes. J. Mass Spectrom. 47, 96-104
34. Schwudke, D., Schuhmann, K., Herzog, R., Bornstein, S. R. and Shevchenko, A. (2011) Shotgun lipidomics on high resolution mass spectrometers. Cold Spring Harb. Perspect. Biol. 3, a004614
35. Mas, S., Touboul, D., Brunelle, A., Aragoncillo, P., Egido, J., Laprevote, O. and Vivanco, F. (2007) Lipid cartography of atherosclerotic plaque by cluster-TOF-SIMS imaging. Analyst 132, 24-26
36. Fiehn, O. (2008) Extending the breadth of metabolite profiling by gas chromatography coupled to mass spectrometry. Trends Analyt. Chem. 27, 261-269
37. Yang, K., Cheng, H., Gross, R. W. and Han, X. (2009) Automated lipid identification and quantification by multidimensional mass spectrometry-based shotgun lipidomics. Anal. Chem. 81, 4356-4368
38. Han, X. and Gross, R. W. (2005) Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom. Rev. 24, 367-412
39. Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L. et al. (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51, 3299-3305
40. Dennis, E. A., Deems, R. A., Harkewicz, R., Quehenberger, O., Brown, H. A., Milne, S. B., Myers, D. S., Glass, C. K., Hardiman, G., Reichart, D. et al. (2010) A mouse macrophage lipidome. J. Biol. Chem. 285, 39976-39985
41. Meikle, P. J., Wong, G., Tsorotes, D., Barlow, C. K., Weir, J. M., Christopher, M. J., MacIntosh, G. L., Goudey, B., Stern, L., Kowalczyk, A. et al. (2011) Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 31, 2723-2732
42. Castillo, S., Gopalacharyulu, P., Yetukuri, L. and Oresic, M. (2011) Algorithms and tools for the preprocessing of LC-MS metabolomics data. Chemom. Intell. Lab. Syst. 108, 23-32
43. Izquierdo-GarcÃa, J. L., Villa, P., Kyriazis, A., del Puerto-Nevado, L., Perez-Rial, S., Rodriguez, I., Hernandez, N. and Ruiz-Cabello, J. (2011) Descriptive review of current NMR-based metabolomic data analysis packages. Prog. Nucl. Magn. Reson. Spectrosc. 59, 263-270
44. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289-300
45. Eliasson, M., Rannar, S. and Trygg, J. (2011) From data processing to multivariate validation - essential steps in extracting interpretable information from metabolomics data. Curr. Pharm. Biotechnol. 12, 996-1004
46. Korman, A., Oh, A., Raskind, A. and Banks, D. (2012) Statistical methods in metabolomics. Methods Mol. Biol. 856, 381-413
47. Oresic, M. (2011) Informatics and computational strategies for the study of lipids. Biochim. Biophys. Acta 1811, 991-999
48. Sugimoto, M., Kawakami, M., Robert, M., Soga, T. and Tomita, M. (2012) Bioinformatics tools for mass spectroscopy-based metabolomic data processing and analysis. Curr. Bioinform. 7, 96-108
49. Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S. et al. (2007) HMDB: the Human Metabolome Database. Nucleic Acids Res. 35, D521-D526
50. Sud, M., Fahy, E., Cotter, D., Brown, A., Dennis, E. A., Glass, C. K., Merrill, A. H., Murphy, R. C., Raetz, C. R. H., Russell, D. W. et al. (2007) LMSD: LIPID MAPS structure database. Nucleic Acids Res. 35, D527-D532
51. Smith, C. A., Maille, G. O., Want, E. J., Qin, C., Trauger, S. A., Brandon, T. R., Custodio, D. E., Abagyan, R. and Siuzdak, G. (2005) METLIN: a metabolite mass spectral database. Therapeutic Drug Monitoring 27, 747-751
52. Cui, Q., Lewis, I. A., Hegeman, A. D., Anderson, M. E., Li, J., Schulte, C. F., Westler, W. M., Eghbalnia, H. R., Sussman, M. R. and Markley, J. L. (2008) Metabolite identification via the Madison Metabolomics Consortium Database. Nat. Biotechnol. 26, 162-164
53. Sies, H. (1997) Oxidative stress: oxidants and antioxidants. Exp. Physiol. 82, 291-295
54. Malle, E., Marsche, G., Arnhold, J. R. and Davies, M. J. (2006) Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim. Biophys. Acta 1761, 392-415
55. Daugherty, A., Dunn, J. L., Rateri, D. L. and Heinecke, J. W. (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94, 437-444
56. Zhang, R., Brennan, M.-L., Fu, X., Aviles, R. J., Pearce, G. L., Penn, M. S., Topol, E. J., Sprecher, D. L. and Hazen, S. L. (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA, J. Am. Med. Assoc 286, 2136-2142
57. Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P. J., Shan, L., Gugiu, B., Fox, P. L. et al. (2002) Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277, 38503-38516
58. Madamanchi, N. R., Vendrov, A. and Runge, M. S. (2004) Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 29-38
59. Keaney, J. F., Larson, M. G., Vasan, R. S., Wilson, P. W. F., Lipinska, I., Corey, D., Massaro, J. M., Sutherland, P., Vita, J. A. and Benjamin, E. J. (2003) Obesity and systemic oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 434-439
60. Matsuura, E., Igarashi, Y., Yasuda, T., Triplett, D. A. and Koike, T. (1994) Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179, 457-462
61. Matsuura, E., Kobayashi, K., Tabuchi, M. and Lopez, L. R. (2006) Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid Res. 45, 466-486
62. Itabe, H., Takeshima, E., Iwasaki, H., Kimura, J., Yoshida, Y., Imanaka, T. and Takano, T. (1994) A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J. Biol. Chem. 269, 15274-15279
63. Dzeletovic, S., Breuer, O., Lund, E. and Diczfalusy, U. (1995) Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225, 73-80
64. Salonen, J. T., Nyyssonen, K., Salonen, R., Porkkala-Sarataho, E., Tuomainen, T.P., Diczfalusy, U. and Bjorkhem, I. (1997) Lipoprotein Oxidation and Progression of Carotid Atherosclerosis. Circulation 95, 840-845
65. Adachi, J., Asano, M., Yoshioka, N., Nushida, H. and Ueno, Y. (2006) Analysis of phosphatidylcholine oxidation products in human plasma using quadrupole time-of flight mass spectrometry. Kobe J. Med. Sci. 52, 127-140
66. Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P. J., Shan, L., Febbraio, M., Hajjar, D. P. et al. (2002) A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277, 38517-38523
67. Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R. et al. (2007) Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 13, 1086-1095
68. Daviet, L. and McGregor, J. L. (1997) Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thromb. Haemostasis 78, 65-69
69. Collot-Teixeira, S., Martin, J., McDermott-Roe, C., Poston, R. and McGregor, J. L. (2007) CD36 and macrophages in atherosclerosis. Cardiovascular Research 75, 468-477
70. Thorne, R. F., Mhaidat, N. M., Ralston, K. J. and Burns, G. F. (2007) CD36 is a receptor for oxidized high density lipoprotein: Implications for the development of atherosclerosis. FEBS letters 581, 1227-1232
71. Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P. J., Shan, L., Febbraio, M., Hajjar, D. P. et al. (2002) A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J. Biol. Chem. 277, 38517-38523
72. Kolodgie, F. D., Burke, A. P., Skorija, K. S., Ladich, E., Kutys, R., Makuria, A. T. and Virmani, R. (2006) Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523-2529
73. Papaspyridonos, M., Smith, A., Burnand, K. G., Taylor, P., Padayachee, S., Suckling, K. E., James, C. H., Greaves, D. R. and Patel, L. (2006) Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 26, 1837-1844
74. MacPhee, C. H., Moores, K. E., Boyd, H. F., Dhanak, D., Ife, R. J., Leach, C. A., Leake, D. S., Milliner, K. J., Patterson, R. A., Suckling, K. E. et al. (1999) Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338, 479-487
75. Ozaki, H., Ishii, K., Arai, H., Kume, N. and Kita, T. (1999) Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis 143, 261-266
76. Davis, B., Koster, G., Douet, L. J., Scigelova, M., Woffendin, G., Ward, J. M., Smith, A., Humphries, J., Burnand, K. G., Macphee, C. H. et al. (2008) Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J. Biol. Chem. 283, 6428-6437
77. Lavi, S., McConnell, J. P., Rihal, C. S., Prasad, A., Mathew, V., Lerman, L. O. and Lerman, A. (2007) Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation. Circulation 115, 2715-2721
78. Thukkani, A. K., McHowat, J., Hsu, F.F., Brennan, M.L., Hazen, S. L. and Ford, D. A. (2003) Identification of α-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108, 3128-3133
79. Engelmann, B. (2004) Plasmalogens: targets for oxidants and major lipophilic antioxidants. Biochem. Soc. Trans. 32, 147-150
80. Leig, J. and Fuchs, B. (2009) Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr. Med. Chem. 16, 2021-2041
81. Hutchins, P. M., Moore, E. E. and Murphy, R. C. (2011) Electrospray MS/MS reveals extensive and nonspecific oxidation of cholesterol esters in human peripheral vascular lesions. J. Lipid Res. 52, 2070-2083
82. Messner, M., Albert, C., McHowat, J. and Ford, D. (2008) Identification of Lysophosphatidylcholine-Chlorohydrin in Human Atherosclerotic Lesions. Lipids 43, 243-249
83. Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G. and Liebisch, G. (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 50, 574-585
84. Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L. et al. (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51, 3299-3305
85. Gertow, K., Nobili, E., Folkersen, L., Newman, J. W., Pedersen, T. L., Ekstrand, J., Swedenborg, J., Kühn, H., Wheelock, C. E., Hansson, G. K. et al. (2011) 12- and 15-lipoxygenases in human carotid atherosclerotic lesions: associations with cerebrovascular symptoms. Atherosclerosis 215, 411-416
86. Golledge, J., Greenhalgh, R. M. and Davies, A. H. (2000) The symptomatic carotid plaque. Stroke 31, 774-781
87. Schartl, M., Bocksch, W., Koschyk, D. H., Voelker, W., Karsch, K. R., Kreuzer, J., Hausmann, D., Beckmann, S. and Gross, M. (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104, 387-392
88. Grønholdt, M. L. M., Wiebe, B. M., Laursen, H., Nielsen, T. G., Schroeder, T. V. and Sillesen, H. (1997) Lipid-rich carotid artery plaques appear echolucent on ultrasound B-mode images and may be associated with intraplaque haemorrhage. Eur. J. Vasc. Endovasc. Surg. 14, 439-445
89. Nissen, S. E. (2002) Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am. J. Cardiol. 89, 24-31
90. Polak, J. F., Shemanski, L., O'Leary, D. H., Lefkowitz, D., Price, T. R., Savage, P. J., Brant, W. E. and Reid, C. (1998) Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. Cardiovascular Health Study. Radiology 208, 649-654
91. Honda, O., Sugiyama, S., Kugiyama, K., Fukushima, H., Nakamura, S., Koide, S., Kojima, S., Hirai, N., Kawano, H., Soejima, H. et al. (2004) Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J. Am. Coll. Cardiol. 43, 1177-1184
92. Seo, Y., Watanabe, S., Ishizu, T., Moriyama, N., Takeyasu, N., Maeda, H., Ishimitsu, T., Aonuma, K. and Yamaguchi, I. (2006) Echolucent carotid plaques as a feature in patients with acute coronary syndrome. Circ. J. 70, 1629-1634
93. Pettinella, C., Lee, S. H., Cipollone, F. and Blair, I. A. (2007) Targeted quantitative analysis of fatty acids in atherosclerotic plaques by high sensitivity liquid chromatography/tandem mass spectrometry. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 850, 168-176
94. Mas, S., Martínez-Pinna, R., Martín-Ventura, J. L., Pérez, R., Gomez-Garre, D., Ortiz, A., Fernandez-Cruz, A., Vivanco, F. and Egido, J. (2010) Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. Diabetes 59, 1292-1301
95. Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867
96. Yudkin, J. S., Kumari, M., Humphries, S. E. and Mohamed-Ali, V. (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link Atherosclerosis 148, 209-214
97. Mayr, M., Grainger, D., Mayr, U., Leroyer, A. S., Leseche, G., Sidibe, A., Herbin, O., Yin, X., Gomes, A., Madhu, B. et al. (2009) Proteomics, metabolomics and immunomics on microparticles derived from human atherosclerotic plaques. Circ. Cardiovasc. Genet. 2, 379-388
98. Hellstrand, K., Asea, A., Dahlgren, C. and Hermodsson, S. (1994) Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J. Immunol. 153, 4940-4947
99. Balkan, J., Kanbagli, Ouml, znur, Hatipoglu, A., Uuml, Ccedil, K. M., Evikbas, U., Ayka, U. et al. (2002) Improving effect of dietary taurine supplementation on the oxidative stress and lipid levels in the plasma, liver and aorta of rabbits fed on a high-cholesterol diet. Biosci. Biotechnol. Biochem. 66, 1755-1758
100. Falk, E., Shah, P. K. and Fuster, V. (1995) Coronary plaque disruption. Circulation 92, 657-671
101. Davies, M. J. (1996) Stability and instability: two faces of coronary atherosclerosis. Circulation 94, 2013-2020
102. Fagerberg, B., Ryndel, M., Kjelldahl, J., Akyürek, L. M., Rosengren, L., Karlström, L., Bergström, G. and Olson, F. J. (2010) Differences in lesion severity and cellular composition between in vivo assessed upstream and downstream sides of human symptomatic carotid atherosclerotic plaques. J. Vasc. Res. 47, 221-230
103. Stegemann, C., Drozdov, I., Shalhoub, J., Humphries, J., Ladroue, C., Didangelos, A., Baumert, M., Allen, M., Davies, A. H., Monaco, C. et al. (2011) comparative lipidomics profiling of human atherosclerotic plaques. Circ. Cardiovasc. Genet. 4, 232-242
104. Willer, C. J. and Mohlke, K. L. (2012) Finding genes and variants for lipid levels after genome-wide association analysis. Curr. Opin. Lipido.l 23, 98-103
105. Duivenvoorden, R., Holleboom, A. G., van den Bogaard, B., Nederveen, A. J., de Groot, E., Hutten, B. A., Schimmel, A. W., Hovingh, G. K., Kastelein, J. J., Kuivenhoven, J. A. et al. (2011) Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging. J. Am. Coll. Cardiol. 58, 2481-2487
106. Sabatine, M. S., Liu, E., Morrow, D. A., Heller, E., McCarroll, R., Wiegand, R., Berriz, G. F., Roth, F. P. and Gerszten, R. E. (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112, 3868-3875
107. Teul, J., Ruperez, F. J., Garcia, A., Vaysse, J., Balayssac, S., Gilard, V., Malet-Martino, M., Martin-Ventura, J. L., Blanco-Colio, L. M., Tunon, J. et al. (2009) Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J. Proteome Res. 8, 5580-5589
108. Turer, A. T., Stevens, R. D., Bain, J. R., Muehlbauer, M. J., van der Westhuizen, J., Mathew, J. P., Schwinn, D. A., Glower, D. D., Newgard, C. B. and Podgoreanu, M. V. (2009) Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 119, 1736-1746
109. Morrow, D. A. and de Lemos, J. A. (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115, 949-952
110. Chace, D. H. and Spitzer, A. R. (2011) Altered metabolism and newborn screening using tandem mass spectrometry: lessons learned from the bench to bedside. Curr. Pharm. Biotechnol. 12, 965-975
111. Kirschenlohr, H. L., Griffin, J. L., Clarke, S. C., Rhydwen, R., Grace, A. A., Schofield, P. M., Brindle, K. M. and Metcalfe, J. C. (2006) Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med. 12, 705-710
112. Roussel, R., Mentre, F., Bouchemal, N., Hadjadj, S., Lievre, M., Chatellier, G., Menard, J., Panhard, X., Le Henanff, A., Marre, M. et al. (2007) NMR-based prediction of cardiovascular risk in diabetes. Nat. Med. 13, 399-400
113. Marre, M., Lievre, M., Chatellier, G., Mann, J. F., Passa, P. and Menard, J. (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br. Med. J. 328, 495
114. Bernini, P., Bertini, I., Luchinat, C., Tenori, L. and Tognaccini, A. (2011) The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples. J. Proteome Res. 10, 4983-4992
115. Wurtz, P., Soininen, P., Kangas, A. J., Makinen, V. P., Groop, P. H., Savolainen, M. J., Juonala, M., Viikari, J. S., Kahonen, M., Lehtimaki, T. et al. (2011) Characterization of systemic metabolic phenotypes associated with subclinical atherosclerosis. Mol. Biosyst. 7, 385-393
116. Wurtz, P., Raiko, J. R., Magnussen, C. G., Soininen, P., Kangas, A. J., Tynkkynen, T., Thomson, R., Laatikainen, R., Savolainen, M. J., Laurikka, J. et al. (2012) High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur. Heart J. 33, 2307-2316
117. LaRosa, J. C., He, J. and Vupputuri, S. (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA, J. Am. Med. Assoc. 282, 2340-2346
118. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357
119. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (1994) Lancet 344, 1383-1389
120. Smith, S. C. Jr., Blair, S. N., Bonow, R. O., Brass, L. M., Cerqueira, M. D., Dracup, K., Fuster, V., Gotto, A., Grundy, S. M., Miller, N. H. et al. (2001) AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104, 1577-1579
121. Stenestrand, U. and Wallentin, L. (2001) Early statin treatment following acute myocardial infarction and 1-year survival. JAMA, J. Am. Med. Assoc. 285, 430-436
122. Rossouw, J. E., Lewis, B. and Rifkind, B. M. (1990) The value of lowering cholesterol after myocardial infarction. N. Engl. J. Med. 323, 1112-1119
123. Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A. and Blasetto, J. W. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160
124. McKenney, J. M., Jones, P. H., Adamczyk, M. A., Cain, V. A., Bryzinski, B. S. and Blasetto, J. W. (2003) Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr. Med. Res. Opin. 19, 689-698
125. Nissen, S. E., Nicholls, S. J., Sipahi, I., Libby, P., Raichlen, J. S., Ballantyne, C. M., Davignon, J., Erbel, R., Fruchart, J. C., Tardif, J. C. et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, J. Am. Med. Assoc. 295, 1556-1565
126. Crouse, J. R., Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O'Leary, D. H., Grobbee, D. E. and Bots, M. L. (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA, J. Am. Med. Assoc. 297, 1344-1353
127. Simon, J. A., Lin, F., Hulley, S. B., Blanche, P. J., Waters, D., Shiboski, S., Rotter, J. I., Nickerson, D. A., Yang, H., Saad, M. et al. (2006) Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am. J. Cardiol. 97, 843-850
128. Sathyapalan, T., Atkin, S. L. and Kilpatrick, E. S. (2008) Variability of lipids in patients with type 2 diabetes taking statin treatment: implications for target setting. Diabetic Med. 25, 909-915
129. McKenney, J. M., Jones, P. H., Bays, H. E., Knopp, R. H., Kashyap, M. L., Ruoff, G. E. and McGovern, M. E. (2007) Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192, 432-437
130. Bergheanu, S. C., Reijmers, T., Zwinderman, A. H., Bobeldijk, I., Ramaker, R., Liem, A. H., van der Greef, J., Hankemeier, T. and Jukema, J. W. (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr. Med. Res. Opin. 24, 2477-2487
131. Jukema, J. W., Liem, A. H., Dunselman, P. H., van der Sloot, J. A., Lok, D. J. and Zwinderman, A. H. (2005) LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr. Med. Res. Opin. 21, 1865-1874
132. Schissel, S. L., Jiang, X., Tweedie-Hardman, J., Jeong, T., Camejo, E. H., Najib, J., Rapp, J. H., Williams, K. J. and Tabas, I. (1998) Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273, 2738-2746
133. Jeong, T., Schissel, S. L., Tabas, I., Pownall, H. J., Tall, A. R. and Jiang, X. (1998) Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J. Clin. Invest. 101, 905-912
134. Park, T. S., Panek, R. L., Rekhter, M. D., Mueller, S. B., Rosebury, W. S., Robertson, A., Hanselman, J. C., Kindt, E., Homan, R. and Karathanasis, S. K. (2006) Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189, 264-272
135. Oestvang, J., Bonnefont-Rousselot, D., Ninio, E., Hakala, J. K., Johansen, B. and Anthonsen, M. W. (2004) Modification of LDL with human secretory phospholipase A2 or sphingomyelinase promotes its arachidonic acid-releasing propensity. J. Lipid Res. 45, 831-838
136. Bolin, D. J. and Jonas, A. (1996) Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J. Biol. Chem. 271, 19152-19158
137. Arimoto, I., Saito, H., Kawashima, Y., Miyajima, K. and Handa, T. (1998) Effects of sphingomyelin and cholesterol on lipoprotein lipase-mediated lipolysis in lipid emulsions. J. Lipid Res. 39, 143-151
138. Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z. B., Wiest, M. M., Nguyen, U. T., Watkins, S. M. and Krauss, R. M. (2010) Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6, 191-201
139. Rise, P., Ghezzi, S., Carissimi, R., Mastromauro, F., Petroni, A. and Galli, C. (2007) Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur. J. Pharmacol. 571, 97-105
140. Laaksonen, R., KataJAMA, J. Am. Med. Assoc.a, M., Paiva, H., Sysi-Aho, M., Saarinen, L., Junni, P., Lutjohann, D., Smet, J., Van Coster, R., Seppanen-Laakso, T. et al. (2006) A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE 1, e97
141. Lusis, A. J. (2012) Genetics of atherosclerosis. Trends Genet 28, 267-275
142. Patel, R. S. and Ye, S. (2011) Genetic determinants of coronary heart disease: new discoveries and insights from genome-wide association studies. Heart 97, 1463-1473
143. Zeller, T., Blankenberg, S. and Diemert, P. (2012) Genomewide association studies in cardiovascular disease - an update 2011. Clin. Chem. 58, 92-103
144. Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S. et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189-197
145. Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T. et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41, 56-65
146. Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J. et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331-1336
147. Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J. et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713
148. Hicks, A. A., Pramstaller, P. P., Johansson, A., Vitart, V., Rudan, I., Ugocsai, P., Aulchenko, Y., Franklin, C. S., Liebisch, G., Erdmann, J. et al. (2009) Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet. 5, e1000672
149. Demirkan, A., van Duijn, C. M., Ugocsai, P., Isaacs, A., Pramstaller, P. P., Liebisch, G., Wilson, J. F., Johansson, A., Rudan, I., Aulchenko, Y. S. et al. (2012) Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations. PLoS Genet. 8, e1002490
150. Ekroos, K., Janis, M., Tarasov, K., Hurme, R. and Laaksonen, R. (2010) Lipidomics: a tool for studies of atherosclerosis. Curr. Atheroscler. Rep. 12, 273-281
151. Kotronen, A., Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M. R., Oresic, M. and Yki-Jarvinen, H. (2009) Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 52, 684-690
152. Chen, X., Liu, L., Palacios, G., Gao, J., Zhang, N., Li, G., Lu, J., Song, T., Zhang, Y. and Lv, H. (2010) Plasma metabolomics reveals biomarkers of the atherosclerosis. J. Sep. Sci. 33, 2776-2783